Rani Therapeutics IPO Raises $84.3M

Aug. 13, 2021 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (Nasdaq:RANI), a clinical stage biotherapeutics company  today announced the final closing of its initial public offering of 7,666,667 shares of its Class A common stock, which includes 1,000,000 shares sold pursuant to the full exercise by the underwriters of their…Read More

Read More
Oyster Point Pharma Reports Q2 2021 Results Including $125M Credit Facility and License Agreement up to $205M

Aug. 05, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma” or “the Company”) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced its financial results for the second quarter of 2021, and provided…Read More

Read More
Elevation Oncology IPO Raises $115M

June 24, 2021 – Elevation Oncology, Inc. (NASDAQ: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16.00…Read More

Read More
Vera Therapeutics IPO Raises $47.8M

May 13, 2021 – Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00…Read More

Read More
Compass, Inc. IPO Raises $450M

April 1, 2021 – Compass, Inc. completed its Initial public offering of 25,000,000 of Class A common stock, to begin trading on the NYSE under the symbol COMP.  The IPO shares were priced at $18/share. Lead underwriters were Goldman Sachs, Morgan Stanley. and Barclays Capital Inc. The FLG partners Jennifer…Read More

Read More